Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARVN002 (low-dose atropine sulfate ophthalmic solution) for slowing myopia progression in children
CTR20222349Phase 3Terminated
- Sponsor
- Arctic Vision
- Start
- Sep 2022
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of MicroPine in myopia, sponsored by Arctic Vision. Started Sep 2022; status: terminated.
02
Drugs
MicroPine
03
Conditions
myopia
Beyond the preview
Go deeper on CTR20222349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222349.